glp-1 weight loss drug market news today Investing in Drugs: Eli Lilly, Novo Nordisk, and Viking Therapeutics in 2026 - and Statistics GLP-1 Drug Market: the rapid

How Your Genetics Influence GLP-1 Response Not everyone responds to GLP-1 medications the same way

Whether you are dealing with rheumatoid arthritis (RA), psoriatic arthritis (PsA), lupus (SLE), Sjgrens disease (SD), or even osteoarthritis (OA), chronic inflammation keeps the immune system in a constant attack mode, leading to: Pain Swelling Stiffness Mobility problems Tissue and cartilage damage This chronic, ongoing inflammation not only makes joints hurt more, but it will worsen blood sugar control, fatigue, brain fog, and increase the risk of heart disease

Insulin resistance in polycystic ovarian syndrome

Mazdutide , a dual GLP-1/glucagon agonist, is in development and shows promising results in early trials, particularly in Asian populations